Form 4: Eli Lilly Executive Sells Shares Under 10b5-1 Trading Plan

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 900 shares of common stock at $803.38 per share on November 8, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Donald A. Zakrowski, a Senior Vice President at Eli Lilly, sold 900 shares of the company's common stock on November 8, 2024.
• The sale was executed at a price of $803.38 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 16, 2023.
• Following the transaction, Mr. Zakrowski directly owns 5,480 shares of Eli Lilly common stock.
• He also indirectly owns 1,715.65 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned sale, which is a common practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among executives at publicly traded companies, including those in the pharmaceutical industry like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold is relatively small compared to the total outstanding shares of Eli Lilly, which is typical for these types of transactions.

Stakeholder Impact

• The impact on shareholders is likely minimal, as the transaction is a routine sale by an executive under a pre-arranged plan.

Key Dates

Keywords

insider trading, Form 4, Rule 10b5-1, stock sale, executive, Eli Lilly, LLY, securities